Semaglutide is the most-discussed weight loss medication in a generation, which means most people arrive at it already holding several half-accurate beliefs—that it is a metabolism drug, that it works by making you burn more, that it is a shortcut, or that it is only for diabetes.
Here is what it actually is and how it works, from the physicians who prescribe it.
At YoungerMeMD this is the medical weight loss program.
The regulatory position
The FDA approved Semaglutide in June 2021 under the brand name Wegovy. It is cleared for chronic weight management in adults who are obese or overweight and have at least one weight-related condition—such as high blood pressure, type 2 diabetes, or high cholesterol.
Two things worth taking from that. It is an approved medication with a defined indication, not an off-label experiment. And the indication is specific: this is a therapy for a clinical picture, not a cosmetic one—which is part of why it requires evaluation rather than a request.
How it actually works
Semaglutide is a GLP-1 receptor agonist. It works primarily on appetite centers in the brain and on gastric emptying.
In practice that means two things.
Appetite regulation. It helps regulate appetite, promote a feeling of fullness, and reduce cravings.
Slower gastric emptying. Food stays in the stomach longer, so fullness lasts longer after eating.
It also improves how the body handles blood sugar.
Now the important part, because it is where most misconceptions live: Semaglutide reduces how much you eat. It does not increase how much you burn, it does not repair a metabolism, and it does not change how your cells handle fuel at the mitochondrial level.
We draw this distinction explicitly against MOTS-c: semaglutide helps you eat less, while MOTS-c helps your cells burn fuel better. Different mechanisms, different goals.
That is not a criticism. Reduced intake is a legitimate and effective mechanism, and for many people it is exactly the constraint. But knowing which lever a medication pulls tells you whether it is the right lever for your problem.
What the results look like
The figures from clinical studies are worth reading with their qualifiers attached.
Average: participants using a weekly dose experienced an average body weight reduction of 5–10%.
Upper range: successful users can achieve up to a 15% reduction. In clinical trials, half of participants lost 15% of their weight, and nearly a third lost 20%.
For comparison: individuals relying solely on lifestyle changes saw an average weight loss of 2.4%.
And the honest caveat: Semaglutide is highly effective for many, but not all, individuals.
The timeline
Many people start to see noticeable changes within the first eight weeks of treatment, with more significant results appearing by week 12.
Individual results vary, and we set expectations against your own picture.
Why it is medically supervised
Our approach places semaglutide within a supervised program rather than treating it as a prescription to be issued and forgotten.
The SlimmerMeMD program uses GLP-1 medications to support weight loss, appetite control and blood sugar management, and includes supplies, labs, and a monthly B12 shot.
The labs matter. This is a medication with a real side effect profile, prescribed to a population that frequently has other metabolic conditions, and monitoring is part of doing it properly.
The step-down phase most people never hear about
This is the most useful thing on this page for anyone thinking past month six, and it addresses the question everybody eventually asks: what happens when I stop?
We offer SlimmerMe: GLP-1 Microdosing—staying on a low, steady dose rather than titrating upward, designed to maintain results, not drive further weight loss.
It is for patients who have already reached their goals on a standard Semaglutide or Tirzepatide program and want a lower-touch way to stay there without stopping GLP-1 support entirely. It is designed as a step-down phase after an active program, and patients typically move into it once they have reached their goals.
The existence of a maintenance phase tells you something real about this class of medication. The appetite regulation is present while the medication is. A plan for what comes after is part of doing this well, and it is better to know that at the start than at the end.
Semaglutide or tirzepatide?
Both are offered, and both support weight management by helping regulate appetite, reduce cravings, and improve how the body handles blood sugar and fullness.
The mechanistic difference: tirzepatide activates GLP-1 and GIP receptors—a dual-pathway approach that regulates insulin, reduces appetite and cravings, increases energy expenditure and slows gastric emptying. Semaglutide works through the GLP-1 pathway.
Which is right for you is a clinical decision. What Is Tirzepatide? The Dual-Agonist, Explained covers the other side.
Where it does not apply
It is worth being clear about the cases where a GLP-1 is not the answer, because we offer those alternatives too.
If the problem is visceral fat specifically—deep abdominal fat that has not responded to a genuine deficit while the rest of you has—that fat does not respond to caloric restriction the way surface fat does. Tesamorelin is the only FDA-approved peptide specifically proven to reduce it.
If the problem is metabolic machinery—post-meal energy crashes, insulin resistance, menopause-related change—MOTS-c works at the cellular level on energy utilization, and it is our top recommendation for menopause weight gain.
If the problem is hormonal—we offer customized bioidentical hormone replacement programs specifically to address weight gain linked to hormonal imbalances.
Sometimes the answer is a GLP-1. Sometimes the answer is that intake was never the constraint. The assessment is what distinguishes them.
Side effects, briefly
Common side effects may include nausea, diarrhea, vomiting, headache and fatigue.
The FDA advises patients to discuss their full medical history with a healthcare professional before beginning treatment, especially if they have symptoms of pancreatitis or gallstones.
That is a real caution and not a formality. More detail in Semaglutide Side Effects and What to Expect Weekly.
Semaglutide is a prescription medication with a defined indication, a real side effect profile, and a maintenance question at the end of it. Which is why it belongs inside a supervised program with labs rather than as a standalone prescription.
Book a consultation to find out whether it fits—and whether intake is actually your constraint.
This article is for general education and is not medical advice. Semaglutide is a prescription medication, FDA-approved for chronic weight management in adults who are obese or overweight with at least one weight-related condition. It is not appropriate for everyone. Discuss your full medical history with a clinician before beginning treatment, particularly any history or symptoms of pancreatitis or gallstones. Individual results vary.
